Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter’s Option to Purchase Additional ...
Geneva, Switzerland, January 11, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the successful completion of the …